Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is one of the
most common leading causes of cancer related deaths. Chronic Schistosoma mansoni and HCV
co-infection accelerates the progression of liver disease increasing incidence of early development
of HCC. Anti-parasitic rule of artemisinin together with its anti-viral and antitumor effects
make this drug a good target for investigation as a prophylaxis against HCC. Molecular Docking
and Dynamics Simulation have improved the quality of healthcare studies through providing
high quality predictions of in silicon effect of drugs. This review aims to discuss repositioning
artemisinin as a prophylactic treatment against development of HCC in patients co infected with
Schistosoma mansoni and HCV, pointing out the rule of Molecular docking and dynamics in
predicting the rate of success of this drug.